Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.
Bottom Line: We found that, compared with baseline, the finite element estimates of hip strength increased from 12 months (5.3%; p < 0.0001) and through 36 months (8.6%; p < 0.0001) in the denosumab group.For the placebo group, hip strength did not change at 12 months and decreased at 36 months (-5.6%; p < 0.0001).In conclusion, treatment with denosumab increased hip and spine strength as estimated by FEA of QCT scans compared with both baseline and placebo owing to positive treatment effects in both the trabecular and cortical bone compartments.
Affiliation: University of California Berkeley, Berkeley, CA, USA; O.N. Diagnostics, Berkeley, CA, USA.Show MeSH
Related in: MedlinePlus
Mentions: For individual subjects at 36 months, changes in hip strength were significantly, but weakly, correlated with changes in spine strength for the denosumab group (r = 0.38; p = 0.02) but not for the placebo group (r = 0.18; p = 0.39) (Fig. 4). At 36 months, spine strength increased in all denosumab-treated subjects and hip strength increased in all but two subjects, whereas both the hip and spine strength decreased for the majority of placebo-treated subjects.
Affiliation: University of California Berkeley, Berkeley, CA, USA; O.N. Diagnostics, Berkeley, CA, USA.